#ICYMI : “Plus Therapeutics (PSTV), the Healthcare sector company, was revisited by a Wall Street analyst…Analyst Justin Walsh from JonesTrading maintained a Buy rating on the stock and has a $32.00 price target. Justin Walsh has given his Buy rating due to a combination of factors surrounding Plus Therapeutics’ clinical advancements and the potential of its lead asset, rhenium obisbemeda.”

Read the Full Article on BusinessInsider.com: https://bit.ly/3U5ePn7

#PSTV #Stocks #Nasdaq